医学
癌症
抗药性
放射治疗
免疫系统
化疗
药品
癌症治疗
免疫疗法
免疫检查点
联合疗法
癌症治疗
肿瘤科
药理学
重症监护医学
免疫学
内科学
生物
微生物学
作者
Yefang Lao,Daoming Shen,Weili Zhang,Rui He,Min Jiang
出处
期刊:Cancers
[MDPI AG]
日期:2022-07-22
卷期号:14 (15): 3575-3575
被引量:18
标识
DOI:10.3390/cancers14153575
摘要
Immune checkpoint inhibitors (ICIs), antagonists used to remove tumor suppression of immune cells, have been widely used in clinical settings. Their high antitumor effect makes them crucial for treating cancer after surgery, radiotherapy, chemotherapy, and targeted therapy. However, with the advent of ICIs and their use by a large number of patients, more clinical data have gradually shown that some cancer patients still have resistance to ICI treatment, which makes some patients unable to benefit from their antitumor effect. Therefore, it is vital to understand their antitumor and drug resistance mechanisms. In this review, we focused on the antitumor action sites and mechanisms of different types of ICIs. We then listed the main possible mechanisms of ICI resistance based on recent studies. Finally, we proposed current and future solutions for the resistance of ICIs, providing theoretical support for improving their clinical antitumor effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI